SOTIO® SO-N102 is developed in collaboration with NBE-Therapeutics as part of a broader multi-target alliance to develop next-generation antibody-drug conjugates (ADCs) for improved cancer therapy. NBE and SOTIO collaborate on the discovery, non-clinical development and manufacturing of novel ADC products against undisclosed targets. The ADC products are based on the NBE proprietary antibody discovery and conjugation platforms, including the NBE Transpo-mAbTM antibody platform, its site-specific SMAC TechnologyTM for site-specific, enzyme-mediated conjugation and its novel ultra-potent anthracycline based toxin platform.

SOTIO will have a global responsibility for clinical development, registration and commercialization of the collaborative ADC products.

This website uses cookies; by continuing to use this page, you consent to their use. About cookies